Phil Skolnick

Summary

Affiliation: DOV Pharmaceutical
Country: USA

Publications

  1. ncbi request reprint Current perspectives on the development of non-biogenic amine-based antidepressants
    P Skolnick
    Neuroscience Discovery, Eli Lilly and Co, Lilly Corporate Center, DC 0510, Indianapolis, IN 46285 0510, USA
    Pharmacol Res 43:411-23. 2001
  2. ncbi request reprint DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile
    Bernard Beer
    DOV Pharmaceutical, Inc, Continental Plaza, 433 Hackensack Avenue, Hackensack, NJ 07601, USA
    J Clin Pharmacol 44:1360-7. 2004
  3. ncbi request reprint The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptors
    Piotr Popik
    Behavioral Neuroscience, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
    J Pharmacol Exp Ther 319:1244-52. 2006
  4. pmc Pharmacological Properties of DOV 315,090, an ocinaplon metabolite
    Dmytro Berezhnoy
    Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, 715 Albany St, Boston, MA 02118, USA
    BMC Pharmacol 8:11. 2008
  5. ncbi request reprint "Broad spectrum" antidepressants: is more better for the treatment of depression?
    Phil Skolnick
    DOV Pharmaceutical, Inc, 433 Hackensack Avenue, Hackensack, NJ 07601, USA
    Life Sci 73:3175-9. 2003
  6. ncbi request reprint Triple reuptake inhibitors ("broad spectrum" antidepressants)
    Phil Skolnick
    DOV Pharmaceutical, Inc, USA
    CNS Neurol Disord Drug Targets 6:141-9. 2007
  7. ncbi request reprint Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor
    Phil Skolnick
    DOV Pharmaceutical, Inc, Hackensack, NJ 08873, USA
    CNS Drug Rev 12:123-34. 2006
  8. ncbi request reprint Beyond monoamine-based therapies: clues to new approaches
    Phil Skolnick
    DOV Pharmaceutical Inc, 433 Hackensack Ave, Hackensack, NJ 07601, USA
    J Clin Psychiatry 63:19-23. 2002
  9. ncbi request reprint Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor
    Phil Skolnick
    DOV Pharmaceutical, Inc, Continental Plaza, 433 Hackensack Avenue, Hackensack, NJ 07601, USA
    Eur J Pharmacol 461:99-104. 2003
  10. ncbi request reprint AMPA receptors: a target for novel antidepressants?
    Phil Skolnick
    DOV Pharmaceutical, Inc, Somerset, New Jersey 08873, USA
    Biol Psychiatry 63:347-8. 2008

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Current perspectives on the development of non-biogenic amine-based antidepressants
    P Skolnick
    Neuroscience Discovery, Eli Lilly and Co, Lilly Corporate Center, DC 0510, Indianapolis, IN 46285 0510, USA
    Pharmacol Res 43:411-23. 2001
    ..Drugs emerging from these strategies may offer significant advantages over currently used antidepressants...
  2. ncbi request reprint DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile
    Bernard Beer
    DOV Pharmaceutical, Inc, Continental Plaza, 433 Hackensack Avenue, Hackensack, NJ 07601, USA
    J Clin Pharmacol 44:1360-7. 2004
    ..Plasma concentrations of DOV 216,303 after doses > 10 mg exceed its reported IC(50) values for inhibition of biogenic amine reuptake...
  3. ncbi request reprint The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptors
    Piotr Popik
    Behavioral Neuroscience, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
    J Pharmacol Exp Ther 319:1244-52. 2006
    ....
  4. pmc Pharmacological Properties of DOV 315,090, an ocinaplon metabolite
    Dmytro Berezhnoy
    Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, 715 Albany St, Boston, MA 02118, USA
    BMC Pharmacol 8:11. 2008
    ....
  5. ncbi request reprint "Broad spectrum" antidepressants: is more better for the treatment of depression?
    Phil Skolnick
    DOV Pharmaceutical, Inc, 433 Hackensack Avenue, Hackensack, NJ 07601, USA
    Life Sci 73:3175-9. 2003
    ....
  6. ncbi request reprint Triple reuptake inhibitors ("broad spectrum" antidepressants)
    Phil Skolnick
    DOV Pharmaceutical, Inc, USA
    CNS Neurol Disord Drug Targets 6:141-9. 2007
    ..This review provides a rationale for developing this class of compound and describes the results of preclinical and clinical studies with a family of triple reuptake inhibitors...
  7. ncbi request reprint Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor
    Phil Skolnick
    DOV Pharmaceutical, Inc, Hackensack, NJ 08873, USA
    CNS Drug Rev 12:123-34. 2006
    ..These findings provide preliminary evidence of a clinically meaningful antidepressant action with a molecule capable of inhibiting the three transmitters most closely linked to major depressive disorder...
  8. ncbi request reprint Beyond monoamine-based therapies: clues to new approaches
    Phil Skolnick
    DOV Pharmaceutical Inc, 433 Hackensack Ave, Hackensack, NJ 07601, USA
    J Clin Psychiatry 63:19-23. 2002
    ..However, these 2 mechanisms may ultimately impact similar cellular endpoints...
  9. ncbi request reprint Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor
    Phil Skolnick
    DOV Pharmaceutical, Inc, Continental Plaza, 433 Hackensack Avenue, Hackensack, NJ 07601, USA
    Eur J Pharmacol 461:99-104. 2003
    ....
  10. ncbi request reprint AMPA receptors: a target for novel antidepressants?
    Phil Skolnick
    DOV Pharmaceutical, Inc, Somerset, New Jersey 08873, USA
    Biol Psychiatry 63:347-8. 2008
  11. ncbi request reprint Modulation of glutamate receptors: strategies for the development of novel antidepressants
    P Skolnick
    DOV Pharmaceutical, Inc Hackensack, New Jersey 07601, USA
    Amino Acids 23:153-9. 2002
    ..These distinct and (on a cellular level) seemingly diametric strategies may converge on intracellular pathways that are also impacted upon by chronic treatment with biogenic amine based agents...
  12. ncbi request reprint Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain
    Anthony S Basile
    DOV Pharmaceutical, Inc, 150 Pierce St, Somerset, NJ 08873 4185, USA
    J Pharmacol Exp Ther 321:1208-25. 2007
    ....
  13. ncbi request reprint Enhancement of antidepressant potency by a potentiator of AMPA receptors
    Xia Li
    Neuroscience Discovery Research, Eli Lilly and Co, Lilly Research Laboratories, Corporate Center, Indianapolis, Indiana, USA
    Cell Mol Neurobiol 23:419-30. 2003
    ....
  14. ncbi request reprint The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity
    Joseph P Tizzano
    Department of Preclinical Pharmacology, DOV Pharmaceutical, Inc, 150 Pierce St, Somerset, NJ 08873 4185, USA
    J Pharmacol Exp Ther 324:1111-26. 2008
    ..In summary, DOV 21947 is effective in causing a sustained and selective reduction in fat content and triglyceride levels in animal models of obesity without significantly altering vital organ function...
  15. ncbi request reprint Anxioselective anxiolytics: can less be more?
    Anthony S Basile
    DOV Pharmaceutical, Inc, 433 Hackensack Avenue, Hackensack, NJ 07601, USA
    Eur J Pharmacol 500:441-51. 2004
    ..This article reviews the nonclinical and clinical studies of "anxioselective" anxiolytics that target GABA(A) receptors and discusses potential mechanisms subserving an anxioselective profile...
  16. ncbi request reprint Triple uptake inhibitors: therapeutic potential in depression and beyond
    Zhengming Chen
    DOV Pharmaceutical, Inc, Somerset, NJ 08873 4185, USA
    Expert Opin Investig Drugs 16:1365-77. 2007
    ....
  17. doi request reprint Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial
    Pierre Tran
    Euthymics Bioscience, Inc, 43 Thorndike Street, Suite S1 3, Cambridge, MA 02141, USA
    J Psychiatr Res 46:64-71. 2012
    ..The efficacy and tolerability of amitifadine for major depressive disorder are being investigated in additional clinical trials...
  18. ncbi request reprint A single residue contributes sensitivity to allosteric modulation of AMPA receptors by LY395153
    Jennifer C Quirk
    Neuroscience Division, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Eur J Pharmacol 454:125-9. 2002
    ....
  19. ncbi request reprint An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study
    Marzena Mackowiak
    Eli Lilly and Co Ltd, Lilly Corporate Center, Indianapolis, IN 46285 0814, USA
    Neuropharmacology 43:1-10. 2002
    ..The regulation of BDNF expression by biarylpropylsulfonamids such as LY451646 may have important therapeutical implications for this class of molecule in the treatment of depression and other CNS disorders...
  20. ncbi request reprint The reinforcing properties of alcohol are mediated by GABA(A1) receptors in the ventral pallidum
    Harry L June
    Psychobiology Program, Department of Psychology, Indiana University Purdue University, Indianapolis, IN 46202, USA
    Neuropsychopharmacology 28:2124-37. 2003
    ..These anti-alcohol properties of betaCCt are primarily mediated via the GABA(A1) receptor. betaCCt may represent a prototype of a pharmacotherapeutic agent to effectively reduce alcohol drinking behavior in human alcoholics...
  21. ncbi request reprint Glutamate and depression: clinical and preclinical studies
    Ian A Paul
    Laboratory of Neurobehavioral Pharmacology and Immunology, Division of Neurobiology and Behavior Research, Department of Psychiatry, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA
    Ann N Y Acad Sci 1003:250-72. 2003
    ....
  22. ncbi request reprint Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease
    MICHAEL J O'NEILL
    Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
    Eur J Pharmacol 486:163-74. 2004
    ..Therefore, we propose that AMPA receptor potentiators offer the potential of a new therapy to halt the progression and perhaps repair the degeneration in Parkinson's disease...
  23. ncbi request reprint Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677
    Piotr Popik
    Behavioral Neuroscience Laboratory, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31 343, Krakow, Poland
    Cell Mol Neurobiol 26:857-73. 2006
    ..5. In summary, DOV 102,677 is an orally active, "balanced" inhibitor of DAT, NET and SERT with therapeutic versatility in treating neuropsychiatric disorders beyond depression...
  24. ncbi request reprint LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease
    Tracey K Murray
    Eli Lilly and Co Ltd, Lilly Research Centre, Surrey, UK
    J Pharmacol Exp Ther 306:752-62. 2003
    ..Therefore, we propose that AMPA receptor potentiators offer the potential of a new disease modifying therapy for Parkinson's disease...